Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Nadim Ahmed Biography and Net Worth

Pres of Cullinan Oncology

Nadim Ahmed is the President and Chief Executive Officer of Cullinan Oncology.

Nadim has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb (BMS), where he served as President, Hematology and at Celgene Corporation (Celgene) where he served as President, Global Hematology & Oncology through its acquisition by BMS. As President, Hematology at BMS, Nadim oversaw multiple product launches and participated as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. During this time at Celgene, he successfully launched multiple cancer medicines, including Pomalyst®, Abraxane® and several key indications for Revlimid®. Nadim has worked with various treatment modalities, including small molecules, biologics and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.

Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping homeless families.

How old is Nadim Ahmed?: Mr. Ahmed is currently 56 years old. There are 5 older executives and no younger executives at Cullinan Oncology. The oldest executive at Cullinan Oncology is Dr. Patrick A. Baeuerle Ph.D., Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board, who is 66 years old. Learn More on Nadim Ahmed's age.
How do I contact Nadim Ahmed?: The corporate mailing address for Mr. Ahmed and other Cullinan Oncology executives is , , . Cullinan Oncology can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Nadim Ahmed's contact information.
Has Nadim Ahmed been buying or selling shares of Cullinan Oncology?: Nadim Ahmed has not been actively trading shares of Cullinan Oncology during the last quarter. Learn More on Nadim Ahmed's trading history.
Who are Cullinan Oncology's active insiders?: Cullinan Oncology's insider roster includes Nadim Ahmed (Pres), Ansbert Gadicke (Director), Jennifer Michaelson (Insider), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Oncology's active insiders.
Are insiders buying or selling shares of Cullinan Oncology?: During the last twelve months, insiders at the sold shares 21 times. They sold a total of 126,339 shares worth more than $1,727,655.68. The most recent insider tranaction occured on February, 1st when insider Corrine Savill sold 40,000 shares worth more than $647,200.00. Insiders at Cullinan Oncology own 8.8% of the company. Learn More about insider trades at Cullinan Oncology.
Information on this page was last updated on 2/1/2024.

Nadim Ahmed Insider Trading History at Cullinan Oncology

Nadim Ahmed Buying and Selling Activity at Cullinan Oncology

Cullinan Oncology Company Overview

Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $25.30

$19.27

$25.72

50 Day Range

MA: $17.32

$15.32

$25.30

2 Week Range

Now: $25.30

$7.64

$25.72

Volume

4,747,157 shs

Average Volume

556,302 shs

Market Capitalization

$1.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.33